Company research

ENOV · NYSE

Enovis Corp

Healthcare · Medical Devices

$22.81

+4.11%

Close on Oct 29, 2026

Research data through 2026-10-28

Long-term research evidence only. No price targets, no trading signals, no recommendations.

Free research · no account required

Pro Investor Academy research

Research data through Oct 28, 2026. Research is updated periodically, not in real time.

Quality

—

Not currently available

Not currently available. Pro Investor Academy holds no current Quality measurement for this company.

Quality research measures durability of the business itself from stored fundamentals: balance-sheet strength, profitability consistency and cash generation. It is a research reading, not a prediction of future returns.

How this is measured

Fundamental Momentum

—

Not currently available

Not currently available. Pro Investor Academy holds no current Fundamental Momentum measurement for this company.

Fundamental Momentum research measures the direction of recently reported company fundamentals compared with the company's own history. It describes reported change, not future price movement.

How this is measured

Capital Returns

Weak

20

of 100 · stored research reading

Stored Capital Returns research reads 20 of 100, recorded as weak. No dividend is recorded for this company, so the reading rests on buybacks and dilution control. Share count has increased at about 4.0% a year in the stored window.

Capital Returns research measures how a company has actually returned cash to shareholders: dividend record, buyback effectiveness, dilution control and how those payments were funded.

How this is measured

Investor intelligence

What Investor adds for ENOV

The research below is part of Investor membership. Values are withheld from this page entirely — nothing premium is loaded into it. Start the free trial and the intelligence you asked for unlocks right here.

Investor

See how this company ranks.

Unlock its Pro Investor Score and ranking across the research universe.

7 days · No credit card required

Investor

Understand the risk before you invest.

Unlock Risk Intelligence, Price Risk, and Market Confirmation.

7 days · No credit card required

Investor

Know why, not just what.

Unlock the Pro Research Brief with What Changed & Why, research history and tensions.

7 days · No credit card required

Investor

See what professional investors are reporting.

Unlock Pro Investor Intelligence: disclosed professional-manager and insider activity beside company research.

7 days · No credit card required

Investor

Ask the research.

Unlock Pro Investor AI to ask questions grounded in Pro Investor Academy research and evidence.

7 days · No credit card required

Investor

Keep researching after today.

Save companies and monitor how their research changes over time.

7 days · No credit card required

Explore other companies in this industry. These are objective industry neighbours, not suggested alternatives.

Want to know what qualified today?

Pro Investor Academy continuously applies its research rules across the eligible universe and surfaces a small number of investments for deeper research when they qualify.

Appears in

Rule-based membership

Membership means the company satisfied a published rule on the latest research build. It is not a recommendation.

Learn the metrics on this page

Plain-English definitions, with the formula and the limitations of each measure.

In the company’s own words

What this company does

Enovis Corporation (the "Company", "Enovis", "we" or "us") is a medical technology company focused on developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows by manufacturing, and distributing high-quality medical devices with a broad range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. Our products address the continuum of patient care from injury prevention to rehabilitation after surgery or injury or from degenerative disease, enabling people to regain or maintain their natural motion. We seek to leverage our Enovis Growth Excellence business system ("EGX"), a set of tools, processes, and culture, to continuously improve our ability to enable great patient outcomes and to drive and fuel growth.

During the year ended December 31, 2025, we completed four acquisitions within our Reconstructive segment and three acquisitions within our Prevention & Recovery segment. These small acquisitions added complementary prevention & recovery product offerings, expanded distribution partners for the Company’s surgical implant products in Europe, and added a complementary surgical product technology. See Note 5 "Acquisitions and Divestitures" for further information.

Our business management system, EGX, is integral to our operations. EGX is our culture and incorporates our values and drives our behaviors. EGX consists of a comprehensive set of tools, and repeatable, teachable processes that we use to drive continuous improvement and create superior value for our customers, shareholders and associates. We believe that our management team’s access to, and experience in, the application of the EGX methodology is one of our primary competitive strengths.

Each year, Enovis associates in every business develop strategic and operating plans that are based on the principle of the Voice of the Customer . In these plans, we are clear about our market realities, our threats, our risks, our opportunities and, most importantly, our vision. Our belief is that when we use the tools of EGX to drive the implementation of these plans, we are able to uniquely provide customers with the world-class quality, delivery, cost and innovation they require. We believe that performance ultimately helps our customers and Enovis sustainably grow and succeed.

Quoted from the business section of this company’s 10-K filed February 26, 2026. Read the filing

General research only. Not personalized advice. Public filings may be delayed, amended, incomplete, or reflect positions that have changed since the reporting date.